Welcome to BioMarket Group!

Analytical Tool - Angiogenesis in Oncology

Additional Information

Published Date Mar 25, 2014
Pages No
License Prices No
PDF Fact Sheet No
Format PDF & Desktop App plus Online Access to Updates (One Year)
Publisher BioSeeker Group

Availability: In stock

$4,650.00

Quick Overview

The ultimate tool for serious players who would like to understand the current competitive field in cancer drug development among anti-angiogenic and vascular targeting agents.
Request free sample pages from Analytical Tool - Angiogenesis in Oncology

"Analytical Tool - Angiogenesis in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in anti-angiogenic drug development for the treatment of cancer. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their progress. This tool provides you with an immense amount of information structured and analyzed to assist you in your work. It is designed to assist you in finding right partners, optimizing your licensing deals, wisely choosing which projects give you the best competitive advantage, and assuring you that your decisions have been based on the most accurate, validated and precise facts available.

Included in this advantageous package are two products already appreciated by many of our customers:


The Package Includes

  • A progress analysis on current and emerging drugs
  • Information on most companies active in anti-angiogenic R&D in oncology
  • Information on key industry related anti-angiogenic drug projects in oncology
  • Data from most important clinical trials
  • Information on early developmental stage projects
  • Possibility of performing advanced searches suited to your individual needs

This Tool will Assist You in:

  • Tracking cutting edge companies, therapies and new technologies
  • Rapid identification of partners & competitors
  • Laying down a comprehensive framework for further analysis of the field
  • Producing presentations surrounding the development of anti-angiogenic drugs in oncology
  • Identifying emerging anti-angiogenic cancer products & key areas of pharmaceutical R&D

*This software application is a searchable database reflects the most recent advances in the field of anti-angiogenic drug development in cancer, in order to help you perform your own analysis, go back to the source data for in-depth information, and present the research and development in tables and graphs suited for your own specific purposes. A significant advantage with BioSeeker’s software applications is that they provide you with well-structured information. Each pipeline drug/project has been carefully defined and classified in categories and subcategories. The main categories include therapy type, effect, mechanism of action (molecular target), indication, stage of development etc. These categories are further organized and classified in sub-categories. In comparison with other available databases, BioSeeker’s software applications give better overview, specific search capabilities and great dynamic reports.



License Prices:

Request free sample pages from Analytical Tool - Angiogenesis in Oncology

Other selected research from the 'Analytical Tool' category:


Analytical Tool - Prostate Cancer
A unique tool for analyzing the complex competitive pressure within the field of prostate cancer. Learn More


Analytical Tool - Angiogenesis in Oncology
The ultimate tool for serious players who would like to understand the current competitive field in cancer drug development among anti-angiogenic and vascular targeting agents. Learn More

Other selected research from the 'R&D' category:


IL-3 Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 257 companies plus partners who are today developing 339 IL-3 pathway targeting drugs in 1225 developmental projects in cancer across 164 different targets. In addition, there are 4 suspended drugs and another 131 drugs where development has been ceased. Learn More


Alpha6 Beta4 Integrin Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 378 companies plus partners who are today developing 534 Alpha6Beta4 integrin pathway targeting drugs in 1796 developmental projects in cancer across 186 different targets. In addition, there is 1 suspended drug and another 209 drugs where development has been ceased. Learn More

Other selected research from the 'Oncology' category:


Analytical Tool - Peptides in Oncology
A unique tool for analyzing the vast amount of strategic possibilities that have emerged in cancer peptide R&D and business development. Learn More


Analytical Tool - Leukemia
A unique tool for analyzing the complex competitive pressure within the different fields of leukemia therapeutics. Learn More

Other selected research from the 'Line of Treatment' category:


Protein Kinase Inhibitors in Oncology Drug Pipeline Update
BioSeeker Group have identified 462 companies plus partners who are today developing 831 PKI drugs in 2912 developmental projects in cancer across 296 different targets. In addition, there are 5 suspended drugs and another 459 drugs where development has been ceased. Learn More


Analytical Tool - Angiogenesis in Oncology
The ultimate tool for serious players who would like to understand the current competitive field in cancer drug development among anti-angiogenic and vascular targeting agents. Learn More